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(≥50yrs), herpes zoster (≥50yrs), and pertussis (≥18yrs) made up 51%, 30%, 16%, 
and 3% of the cost, respectively. Among those aged ≥50 years, influenza, 
pneumococcal disease, herpes zoster, and pertussis made up 31%, 44%, 24%, and 
1% of the cost, respectively. Most (82%) pneumococcal costs stemmed from non-
bacteremic pneumococcal pneumonia (NPP). Direct medical costs accounted for 
91% of total pneumococcal burden, but only 27%, 28%, and 42% of total economic 
burden due to influenza, herpese zoster, and pertussis, respectively. Sensitivity 
analysis revealed that estimated influenza rates and costs per case, NPP 
incidence and directs costs, and herpes zoster incidence rates and indirect costs 
impacted the model most. CONCLUSIONS: Cost attributable to adult VPD in the 
United States is substantial. Broadening adult immunization efforts beyond 
influenza only may help reduce the economic burden of adult VPD, and a 
pneumococcal vaccination effort, primarily focused on reducing NPP, may be a 
logical place to start.  
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OBJECTIVES: To determine the epidemiologic and economic burdens  
of tuberculosis (TB) in Asia. METHODS: A systematically review of primary 
studies in Asia was conducted. We searched MEDLINE, PUBMED, EMBASE, 
Science Direct, CNKI from January 1, 2000 to July 15, 2012; and websites of 
relevant countries and international organizations. RESULTS: TB prevalence, 
incidence and mortality in the region have declined since 1990 and status relate 
to the economy of the country. In 2010, there were 8.8 million incident cases of 
TB (128/100000 population). Most of the cases occurred in Asia (59%) and Africa 
(26%). India and China accounted for 40% of new and relapse TB cases. In 2006, 
TB caused India to lose a 23.7 billion US$. The mean direct cost was US$34.9  
and mean indirect cost was $526.9. The total cost per patient was $562.7. In 
China, low income patients paid $149 to $724 for medical costs for a treatment 
course (42% to 119% of annual household income). In Philippines, the economic 
losses totaled PhP8 billion (US$145 million) and costs of treating all cases 
requires PhP475–1625 million (US$8–29 million) annually. In Cambodia, TB is the 
second largest cause of mortality. Monthly household costs were US$124/ 
patients ($135 for TB-HIV patients and $260 for resistant-TB patients); the 
average monthly income in Cambodia is $168. In Tajikistan, Patients and their 
households faced mean expenditures of US$ 396; (median US$ 282) related to a 
TB episode. CONCLUSIONS: Although most countries in Asia have done many 
efforts on TB control, the absolute number of patient is large that more efforts 
need to take to achieve the goal of 50% reduction in 2015 from 1990 set by WHO. 
More researches are recommended to study the economic burden in specific 
countries.  
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OBJECTIVES: To describe the cost of outbreak of meningococcal disease in 
Cartagena - Colombia. METHODS: The cost of meningococcal disease outbreak 
from February 21st thru March 21st2012, were described. The suspected cases 
were detected in the Children´s Hospital Napoleon Franco Pareja, House of the 
Child (HC) and they were reported to the Departamento Administrativo Distrital 
de Salud (DADIS, for acronym in Spanish). We ran an active surveillance program 
in the neighborhood cases. The investigation costs of the outbreak control, 
surveillance and health care cost were estimated. RESULTS: During 
meningococcal disease outbreak and following 1 month of active surveillance, a 
total of 6 cases were detected; from which one suspected case, one probable case 
and four were confirmed cases. The average patient age was 4.6 years. 50% of the 
cases died, 33% of the cases had meningitis, meningococcemia and myocarditis. 
66% of the cases had culture specimen positive with Neisseria meningitidis. 5/6 
cases (83%) had RT-PCR positive with Neisseria meningitidis. All N. meningitidiswere 
serogroup B. 50 doses of ceftriaxone were administered as prophylaxis. DADIS 
did not recommend meningococcal vaccination and the proper vaccine was not 
available at the time. The costs of meningococcal outbreak were estimated as 
follows: Cost of control of the outbreak (US $ 735), disease surveillance phase (US 
$ 3,935) and health care cost was US $ 4.670. CONCLUSIONS: All cases were 
caused by N. meningitidis serogroup B. The absence of vaccination involves lower 
costs in control of the outbreak.  
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OBJECTIVES: Patients with COPD are at increased risk for lung infections, such as 
pneumonia. However, few studies have evaluated the impact of pneumonia on 
health care resource utilization (HCRU) and cost in this population. The objective 
of this study is to estimate HCRU and cost in COPD patients with newly acquired 
pneumonia, compared to those without pneumonia. METHODS: A retrospective 
analysis using MarketScan® Commercial Claims and Encounters and Medicare 
Supplemental Databases was conducted. COPD patients with and without newly 
diagnosed pneumonia between January 1, 2005 and September 30, 2010 were 
identified. Propensity score matching was used to create a one-to-one matched 
cohort. Patient demographics, comorbidities measured by Charleston 
Comorbidity Index (CCI), and medication use were evaluated before and after 
matching. HCRU, including the number of hospitalizations, emergency room 
(ER), and outpatient visits, length of hospital stay (LOS), and associated health 
care costs were assessed during the 12-month follow up. Two-part models and 
gamma regression models were conducted to compare costs between groups 
after matching. RESULTS: In the baseline cohort of 520,008 patients, newly 
acquired pneumonia patients were older (mean age: 70 vs. 63 years) and sicker 
(CCI: 3.25 vs. 2.67). After matching, no baseline covariates were statistically 
different between groups. In the matched cohort of 168,260 patients, one-year 
mean HCRU after pneumonia onset was significantly higher (all p<0.0001) for 
inpatient visits (1.2 vs. 0.29), ER visits (1.9 vs. 0.68), outpatient visits (34.97 vs. 
23.1) and LOS (7.3 vs. 1.3 days) than the control cohort. Estimated one-year mean 
costs were higher in the pneumonia cohort with differences in: inpatient costs 
$14,353 (95% CI: $14,037, $14,690), outpatient costs $6,891 ($6,706, $7,075), 
prescription drug costs $1,104 ($1,054, $1,152) and total costs $23362 ($22,969, 
$23,787). CONCLUSIONS: Our study demonstrates elevated HCRU and costs in 
COPD patients after acquiring pneumonia.  
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OBJECTIVES: The cost of antibiotics is always an area of concern in treating RTI. 
The purpose of the current study was to determine the contribution of costs of 
antibiotics on the overall prescription costs in paediatric patients. METHODS: 
The study was carried out at a pediatric outpatient setting where data of 688 
patients, below 18 years of age, was captured over a period of one year from the 
“Wise-kid” software. RESULTS: RTI was most common in the age group of 1-3 Y 
(32%) and 3-6 Y (30%). It affects the patients mostly in winter (35%) followed by 
autumn (25%). Antibiotic prescribed from NLEM-2011 were found to be 92%. All 
the antibiotics were prescribed by oral route with brand name only. Percentage 
of encounters with antibiotics in RTI, were highest in acute otitis media (AOM, 
89%), followed by lower respiratory tract illness (LRTI, 76%), tonsillitis (71%), 
upper respiratory tract infection (URTI) + bronchospasm (17%), URTI (13%) and 
influenza like illness (ILI, 13%). The average cost of treatment was maximum for 
AOM (INR186±7; 1USD=approx INR55) followed by LRTI, ILI, URTI (181±11, 125±6 
& 120±2, respectively in INR). While the average cost spent on antibiotic 
treatment was INR 82±8. Of total cost, 17% was spent on the utilization of 
antibiotics.The order for cost spent on use of different class of drug were cold & 
cough combinations (37%) > NSAIDs (9%) > nasal drops. The contribution of 
antiasthmatics, antihistamines & antibiotics was found to be 6% each. Among 
antibiotics, maximum cost were spent on the use of amoxicillin+clavulanic acid 
combination (66%) followed by the cost spent on the prescribing of azithromycin, 
cefpodoxime, clarithromycin, cephalexin & ofloxacin (24%, 4%, 4%, 1.5% & 1% 
respectively). CONCLUSIONS: The results indicate that less than 20% costs were 
spent on antibiotics for the treatment of RTI. These results build the evidence for 
the cost of treating RTI in children.  
 
PIN47  
HEALTH CARE RESOURCE UTILIZATION, COSTS, AND ADVERSE EVENTS IN THE 
OUTPATIENT TREATMENT OF ASPERGILLOSIS WITH VORICONAZOLE IN THE 
UNITED STATES  
Durden E1, Chaudhari P2, McMorrow D3, Fowler R4, Horn D5 
1Truven Health Analytics, Austin, TX, USA, 2Astellas Pharma US, Deerfield, IL, USA, 3Truven 
Health Analytics, Cambridge, MA, USA, 4Truven Health Analytics, Washington, DC, USA, 5David 
Horn, LLC, Doylestown, PA, USA  
OBJECTIVES: To evaluate the occurrence and associated health care utilization 
and costs of potential adverse events (AEs) associated with outpatient 
voriconazole use among patients with aspergillosis. METHODS: Commercially-
insured adults aged ≥18 years with at least one medical claim with a diagnosis  
of aspergillosis (ICD-9-CM 117.3 or 484.6) between July 1, 2004-March 1, 2011 and 
outpatient voriconazole treatment on or after the index diagnosis were identified 
from the MarketScan Research Databases. Patients were required to have ≥6 
months of pre-index and ≥1 month of post-index health plan and pharmacy 
benefit enrollment. Patients with an aspergillosis diagnosis in the pre-index 
period were excluded. Potential AEs, as indicated in the package insert  
for voriconazole, were identified via diagnosis codes and were evaluated for 
periods during active treatment plus 7 days. AE-related monitoring , such as 
organ function tests and visits with ophthalmologists, were also evaluated. Total 
all-cause costs and potential AE-related costs were calculated. RESULTS: A total 
of 1511 patients treated with voriconazole were identified. The most common 
conditions observed during active treatment with voriconazole plus 7 days were 
fever (15.1%), tachycardia (12.2%), acute kidney failure (8.9%), and 
nausea/vomiting (8.4%). AE-related inpatient admissions and outpatient 
physician office visits were observed for 19.9% and 40.8% of patients, 
respectively. Outpatient AE-related organ function testing, aspergillosis-related 
laboratory tests, including therapeutic drug monitoring, and at least one office 
visit with an ophthalmologist, was observed among 16.3%, 34.5%, 18.1%  
of patients, respectively. Average total, aspergillosis-related costs during follow-
up of patients treated with voriconazole were $35,968 ± $68,590. Average total 
costs associated with adverse events and adverse event monitoring were $3,772 
± $30,057 or 10.5% of total average costs. CONCLUSIONS: Conditions suggestive 
of AEs associated with voriconazole occurred frequently, and were associated 
